RT Journal Article
T1 Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study.
A1 Trujillo-Santos, Javier
A1 Farge-Bancel, Dominique
A1 Pedrajas, Jose Maria
A1 Gomez-Cuervo, Covadonga
A1 Ballaz, Aitor
A1 Braester, Andrei
A1 Mahe, Isabelle
A1 Villalobos, Aurora
A1 Porras, Jose Antonio
A1 Monreal, Manuel
K1 LMWH
K1 Cancer
K1 Cohort
K1 Dalteparin
K1 Enoxaparin
K1 Recurrences
K1 Tinzaparin
K1 Venous thromboembolism
AB Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. The objective of the RIETECAT study was to compare the long-term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active cancer. We used the data from the multicenter, multinational RIETE registry to compare the rates of VTE recurrences, major bleeding, or death over 6 months in patients with active cancer and acute VTE using full doses of enoxaparin versus dalteparin or tinzaparin, and a multivariable Cox proportional hazard model was used to analyze the primary end point. From January 2009 to June 2018, 4451 patients with active cancer received full doses of the study drugs: enoxaparin, 3526 patients; and dalteparin or tinzaparin, 925 (754 + 171) patients. There was limited difference in VTE recurrences (2.0% vs 2.5%) and mortality rate (19% vs 17%) between the enoxaparin and dalteparin or tinzaparin subgroups. However, there was a slight numerical increase in major bleeding (3.1% vs 1.9%). Propensity score matching confirmed that there were no differences in the risk for VTE recurrences (adjusted hazard ratio [aHR], 0.81; 95% confidence interval [CI], 0.48-1.38), major bleeding (aHR, 1.40; 95% CI, 0.80-2.46), or death (aHR, 1.07; 95% CI, 0.88-1.30) between subgroups. In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.
PB Wiley-Blackwell Publishing
YR 2022
FD 2022-04-20
LK http://hdl.handle.net/10668/22528
UL http://hdl.handle.net/10668/22528
LA en
NO Trujillo-Santos J, Farge-Bancel D, Pedrajas JM, Gómez-Cuervo C, Ballaz A, Braester A, et al. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. Res Pract Thromb Haemost. 2022 Jun 3;6(4):e12736
DS RISalud
RD Mar 13, 2025